HoldsUp

Chris Williamson

Chris Williamson is a podcast host who covers topics surrounding human aging, biology, and health. His discussions include interviews with researchers such as Dr. David Sinclair on cellular age reversal, dietary habits, and longevity supplements. No academic publications are listed in the provided context.

10 claims checked on air: 1 context 2 contradicted 3 overstated 3 supported 1 unverified

What they said on air

0:20:15overstatedlow“Age Reversal Is Coming.” Everything You Need To Know - Dr D

AG1 NextGen was tested in four clinical trials, showing it improved key nutrient levels in 3 months and increased healthy gut bacteria tenfold.

"And they've taken it a step further with AG1 NextGen, backed by four clinical trials. In those trials it was shown to fill common nutrient gaps, improve key nutrient levels in just 3 months, and increase healthy gut bacteria by 10 times, even in people who already eat well." (said at 0:20:15)

The host's statement overstates the scientific body of evidence. Published research evaluating AG1 includes two small, manufacturer-funded randomized crossover/placebo-controlled human trials (PMID 41988471, n=20 for 2 weeks; PMID 39352252, n=30 for 4 weeks) and two in vitro gastrointestinal models (PMID 38248338, PMID 39065031), rather than four full clinical trials. While the 2-week crossover trial demonstrated that AG1 filled micronutrient gaps (such as vitamins A, C, and E) in trained adults who already ate well, neither published human trial lasted 3 months, nor did they show a tenfold increase in total healthy gut bacteria. Instead, the 4-week and 2-week trials observed selective enrichment of specific probiotic species (such as Bifidobacterium and Lactobacillus spp.) without global shifts in microbiome diversity.

0:30:36contradictedmoderate“Age Reversal Is Coming.” Everything You Need To Know - Dr D

GLP-1 receptor agonists slow motility through the gut, which helps with conditions such as SIBO, Candida, and H. pylori.

"Well, I mean, I know that some of the proposed positive effects for GLP-1s include slowing motility through the gut, which actually helps with things like SIBO or candida or H. pylori because the pace this is why every body every bro lifter that's listening to this you you at some point in your life have glanced off the bottom of SIBO or maybe have it right now" (said at 0:30:36)

The speaker gets the physiological relationship backwards. While GLP-1 receptor agonists do slow gastrointestinal motility and gastric emptying, delayed gut transit and impaired migrating motor complex activity are primary pathophysiological causes and risk factors for small intestinal bacterial overgrowth (SIBO) and fungal overgrowth (Candida), not treatments. Prokinetics that accelerate motility are used therapeutically for SIBO, whereas GLP-1 receptor agonists significantly increase the risk of developing SIBO.

0:34:59overstatedmoderate“Age Reversal Is Coming.” Everything You Need To Know - Dr D

In clinical trials, Timeline (urolithin A) increased mitochondrial renewal by over 40% in 16 weeks along with improvements in overall energy.

"In clinical trials, people saw mitochondrial renewal increased by more than 40% in just 16 weeks along with improvements in their overall energy." (said at 0:34:59)

Randomized placebo-controlled clinical trials of Urolithin A (Timeline / Mitopure) administered over 4 months (16 weeks) have evaluated biomarkers of mitophagy (mitochondrial recycling/renewal), muscle strength, endurance, and cellular metabolism. While trials observed increased expression of mitophagy-related proteins, reductions in plasma acylcarnitines, and modest improvements in muscle strength (~12%) or muscle endurance, primary functional endpoints (such as peak power output in middle-aged adults or maximal ATP production and 6-minute walk distance in older adults) did not achieve statistically significant improvements over placebo. Framing these biomarker changes as a definitive '>40% increase in mitochondrial renewal' and conflating them with direct improvements in 'overall energy' overstates the clinical findings.

0:53:44supportedmoderate“Age Reversal Is Coming.” Everything You Need To Know - Dr D

Function lab testing detects early signals associated with more than 50 types of cancer.

"Function gives you access to more than 160 advanced lab tests spanning hormones, heart health, kidney function, and even detects early signals linked to more than 50 types of cancer." (said at 0:53:44)

Multi-cancer early detection (MCED) blood testing offered through health platforms (such as the Galleri test by GRAIL) evaluates cell-free DNA (cfDNA) methylation patterns to screen for cancer signals. Clinical validation in a large independent cohort of 4,077 participants (CCGA study substudy 3) confirmed that the test detected cancer signals across more than 50 distinct cancer types with 99.5% specificity, though sensitivity was considerably higher in late stages (77.0% in stage III, 90.1% in stage IV) compared to early stages (16.8% in stage I, 40.4% in stage II).

1:05:08needs contexthigh“Age Reversal Is Coming.” Everything You Need To Know - Dr D

The American Medical Association evaluated the balance of stomach bleeding risks against cardiovascular event reduction and concluded against generalized baby aspirin use for the broad population.

"The American Medical Association weighed the risk of stomach bleeding and other complications versus lowering the amount of risk of cardiovascular events and came to the conclusion that looking across everybody it doesn't make sense." (said at 1:05:08)

The speaker accurately describes the substantive conclusion of major US clinical guidelines, but attributes the decision to the American Medical Association (AMA) rather than the US Preventive Services Task Force (USPSTF) (whose recommendation statement was published in the Journal of the American Medical Association, JAMA) and the American College of Cardiology/American Heart Association (ACC/AHA). In 2022, the USPSTF concluded after extensive systematic review and microsimulation modeling that routine low-dose aspirin for primary prevention across the general population is not supported: in adults aged 60 and older, initiating aspirin carries no net benefit due to gastrointestinal bleeding and intracranial hemorrhage risks, and in adults aged 40 to 59 with elevated cardiovascular risk (>=10%), the net benefit is small and requires individualized clinical decision-making.

1:05:40overstatedvery low“Age Reversal Is Coming.” Everything You Need To Know - Dr D

Taking baby aspirin has been shown to offer cardiovascular benefits in people who have elevated levels of lipoprotein(a).

"there's a group of people, for example, where it does make sense to take baby aspirin. It's been shown that there can be benefits, and it's those people, just as an example, who have high levels of lipoprotein(a) or Lp(a)." (said at 1:05:40)

While observational cohort studies (such as MESA) and genetic subgroup analyses have suggested an association between aspirin use and reduced coronary heart disease or myocardial infarction events in individuals with elevated lipoprotein(a) or LPA variants, systematic reviews and meta-analyses have found no statistically significant reduction in overall major adverse cardiovascular events (MACE) and note that the overall certainty of evidence is very low. Dedicated randomized controlled trials are still lacking.

1:42:37supportedhigh“Age Reversal Is Coming.” Everything You Need To Know - Dr D

Globally, 1 billion people are obese and half a billion people are starving.

"A billion people that are obese and half a billion people that are starving. It's like the number one leading cause of malnutrition globally is obesity." (said at 1:42:37)

The speaker's figures and characterization closely align with global health surveillance data. A comprehensive 2024 pooled analysis by the NCD Risk Factor Collaboration published in The Lancet (incorporating data from 3,663 population-representative studies with 222 million participants) established that by 2022, over 1 billion people globally were living with obesity (including ~879 million adults and ~159 million children and adolescents). The study also confirmed that obesity has overtaken underweight as the leading form of malnutrition in the vast majority of countries (in 89% of countries for women and 73% for men). Furthermore, global reports by the UN Food and Agriculture Organization (FAO) estimate that between 700 and 800 million people (around 735 million) experience hunger and undernourishment worldwide, placing the speaker's 'half a billion' estimate in the general range.

1:42:37contradictedhigh“Age Reversal Is Coming.” Everything You Need To Know - Dr D

Obesity is the leading cause of malnutrition globally.

"It's like the number one leading cause of malnutrition globally is obesity." (said at 1:42:37)

Obesity is not the cause of malnutrition; rather, international public health authorities (such as the World Health Organization and the Lancet Commission) classify overweight and obesity as a distinct form of malnutrition (overnutrition). Malnutrition encompasses three broad groups of conditions: undernutrition (wasting, stunting, underweight), micronutrient-related malnutrition, and overweight/obesity. Global epidemiological data show that obesity has become the most prevalent form of malnutrition in many countries, driven by dietary changes (such as ultra-processed foods) and physical inactivity, but it is a manifestation of malnutrition rather than its leading cause.

1:42:52unverifiedvery low“Age Reversal Is Coming.” Everything You Need To Know - Dr D

Approximately 11% of United States adults have used a GLP-1 receptor agonist medication.

"Currently around about 11% of US adults, 29 million Americans ever used a GLP-1, 15%." (said at 1:42:52)

No peer-reviewed records indexed in PubMed containing the specific national prevalence figure (approximately 11% to 12% of US adults reporting ever using a GLP-1 receptor agonist) were located among the fetched abstracts. The cited statistic originates from national public opinion polling (such as the May 2024 Kaiser Family Foundation Health Tracking Poll, which found approximately 12% of US adults had ever taken a GLP-1 drug), but because these survey data are primarily published in survey reports rather than peer-reviewed indexed abstracts retrieved here, the claim remains unverified in this search. This does not mean the statistic is false.

1:43:30supportedhigh“Age Reversal Is Coming.” Everything You Need To Know - Dr D

About 40% of adults in the United States have obesity.

"About 40% of US adults have obesity." (said at 1:43:30)

According to nationally representative surveillance data from the Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NHANES), the prevalence of obesity among US adults aged 20 and older is approximately 40% (39.8% in 2015–2016 and 41.9%–42.4% in recent cycles). The speaker's statement accurately reflects national epidemiological data.

Fact-checked episodes

Publications

No PubMed publication profile has been built for this speaker yet.